Skip to main content

PIK3CA Biological Pathways Reviews

Videos

Anna Martling, MD, Karolinska Institutet
Videos
01/28/2025
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD, discusses study results which found that adjuvant daily aspirin reduced the risk of colorectal cancer recurrence among patients with PI3K alterations.
Anna Martling, MD, PhD,...
01/28/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the newest data on inavolisib from the INAVO120 trial.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/03/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including the agents targeting PI3K signaling.
In this video, a panel of...
01/03/2025
Oncology
Seth Wander, MD, PhD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
Videos
01/02/2025
Seth Wander, MD; Kelly McCann, MD, PhD; Janice Lu, MD, PhD; Megan Kruse, MD
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of experts discuss PIK3CA-mutant metastatic breast cancer, including an overview of the PI3 kinase pathway in cancer.
In this video, a panel of...
01/02/2025
Oncology
Alberto Montero, MD, UH Seidman Cancer Center
Videos
10/17/2024
Alberto Montero, MD
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses phase 1/2 study results which demonstrated that STX-478 shows promise in patients with heavily pre-treated PI3Kα-mutated solid tumors.
Alberto Montero, MD, discusses...
10/17/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/24/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD, MPH, describes the currently enrolling and ongoing INAVO121 trial, evaluating inavolisib vs alpelisib, both in combination with fulvestrant, for patients with PIK3CA-mutated, hormone receptor-positive,...
Demetria Smith-Graziani, MD,...
09/24/2024
Oncology
Heather McArthur, MD
Videos
09/16/2024
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses results from the phase 3 CAPItello-290 trial which evaluated capivasertib plus paclitaxel as first-line treatment for patients with metastatic triple-negative breast cancer.
Heather McArthur, MD, discusses...
09/16/2024
Oncology
Demetria Smith-Graziani, MD, MPH, Winship Cancer Institute
Videos
09/03/2024
Demetria J. Smith-Graziani, MD, MPH
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD, MPH, shares insights from the results of the phase 3 INAVO120 study, evaluating the addition of inavolisib to palbociclib and fulvestrant for patients with PIK3CA-mutated, HR-positive, HER2-negative advanced...
Demetria Smith-Graziani, MD,...
09/03/2024
Oncology
Daniel Rosas, MD
Videos
03/20/2026
Daniel Rosas, MD, discusses second-line treatment options for patients with advanced lung cancer who experience progression on chemoimmunotherapy.
Daniel Rosas, MD, discusses second-line treatment options for patients with advanced lung cancer who experience progression on chemoimmunotherapy.
Daniel Rosas, MD, discusses...
03/20/2026
Oncology
Sarah Premji, MD
Videos
03/20/2026
Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.
Sarah Premji, MD, discusses whether emerging oral SERDs differ in HR-positive, HER2-negative breast cancer.
Sarah Premji, MD, discusses...
03/20/2026
Oncology
Edward Garon, MD
Videos
03/19/2026
Edward B. Garon, MD, MS
Edward Garon, MD, discusses the evolving role of biomarkers in enabling tumor-agnostic drug approvals across oncology.
Edward Garon, MD, discusses the evolving role of biomarkers in enabling tumor-agnostic drug approvals across oncology.
Edward Garon, MD, discusses the...
03/19/2026
Oncology
Julio Chavez, MD
Videos
03/19/2026
Julio Chavez, MD
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews current and emerging treatment options for patients with relapsed/refractory diffuse large B-cell lymphoma.
Julio Chavez, MD, reviews...
03/19/2026
Oncology
Richard Furman, MD
Videos
03/19/2026
Richard Furman, MD
Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.
Richard Furman, MD, discusses early results from the CLL-17 trial, underscoring the need for longer follow-up before defining optimal frontline strategies for treatment-naïve patients with chronic lymphocytic leukemia.
Richard Furman, MD, discusses...
03/19/2026
Oncology
Adam Brufsky, MD, PhD
Videos
03/19/2026
Adam Brufsky, MD, PhD
Adam Brufsky, MD, PhD, discusses the role of ctDNA and MRD in early-stage breast cancer.
Adam Brufsky, MD, PhD, discusses the role of ctDNA and MRD in early-stage breast cancer.
Adam Brufsky, MD, PhD, discusses...
03/19/2026
Oncology
Angeles Secord, MD
Videos
03/19/2026
Angeles Secord, MD, discusses the evolving role of HRD as a biomarker and the need for improved patient selection in advanced ovarian cancer.
Angeles Secord, MD, discusses the evolving role of HRD as a biomarker and the need for improved patient selection in advanced ovarian cancer.
Angeles Secord, MD, discusses...
03/19/2026
Oncology
Midun Mala, MD
Videos
03/19/2026
Midhun Malla, MD, MS
Midun Mala, MD, assesses the use of adjuvant HAI pump therapy in patients with resected oligometastatic colorectal cancer with liver-only metastases.
Midun Mala, MD, assesses the use of adjuvant HAI pump therapy in patients with resected oligometastatic colorectal cancer with liver-only metastases.
Midun Mala, MD, assesses the use...
03/19/2026
Oncology
Arnab Basu, MD
Videos
03/19/2026
Arnab Basu, MD, discusses emerging bladder preservation strategies in muscle-invasive bladder cancer in the setting of novel neoadjuvant therapies.
Arnab Basu, MD, discusses emerging bladder preservation strategies in muscle-invasive bladder cancer in the setting of novel neoadjuvant therapies.
Arnab Basu, MD, discusses...
03/19/2026
Oncology
Scott Tagawa, MD
Videos
03/19/2026
Scott Tagawa, MD
Scott Tagawa, MD, discusses the principles and clinical applications of targeted radionuclide therapy in oncology.
Scott Tagawa, MD, discusses the principles and clinical applications of targeted radionuclide therapy in oncology.
Scott Tagawa, MD, discusses the...
03/19/2026
Oncology
OLN

PIK3CA

ALIASES

Phosphatidylinositol 3-kinase catalytic subunit

References

PIK3CA (phosphatidylinositol 3-kinase catalytic subunit) is an oncogene that encodes one piece (a subunit) of an enzyme called phosphatidylinositol 3-kinase (PI3-Kinase).1 PIK3CA plays a role in the control of cell growth, cell survival, and cell migration. Mutations in the PIK3CA gene can lead to uncontrolled cell growth and contribute to the proliferation and progression of cancer.2 

The PI3-Kinase pathway is one of many signaling pathways that are important for cell growth, transformation, adhesion, apoptosis, survival and invasion.3 PI3-Kinases are heterodimeric lipid kinases composed of catalytic and adaptor/regulatory subunits encoded by separate genes and alternative splicing. In the case of oncogenes, including PIK3CA, genetic changes such as a mutation can result in a cellular state whereby the PIK3CA gene product is constantly activated. Ultimately, this contributes toward uncontrolled cellular growth and other features that are the hallmarks of cancer.1

Gene amplifications, deletions and more recently, somatic missense mutations in the PIK3CA gene have been reported in many human cancer types including cancers of the colon, breast, brain, liver, stomach and lung. These somatic missense mutations were proposed to increase the kinase activity of PIK3CA contributing to cellular transformation.3

PIK3CA mutations are found in 20% to 25% of colon cancers and 10% of rectal cancers. In addition to colorectal cancer, PIK3CA oncogene mutations are involved in several human cancers including breast cancer, ovarian cancer, and non-small cell lung cancer (NSCLC).2

Understanding the Role of PIK3CA

News

Conference Coverage
12/03/2024
Allison Casey
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study, the PI3K-alpha inhibitor, STX-478, showed promise among patients with PIK3CA-mutant solid tumors and/or HR-positive, HER2-negative breast cancer.
According to a phase 1/2 study,...
12/03/2024
Oncology
Conference Coverage
12/03/2024
Allison Casey
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial, LOXO-783 demonstrated a proof of mutant selectivity among patients with PIK3CA H1047R-mutant solid tumors. However, the rate of diarrhea prevented the determination of an optimal preclinical dose.
In the PIKASSO-01 trial,...
12/03/2024
Oncology
News
11/05/2024
Allison Casey
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center cohort study, there was a substantial overall survival disparity, with differing frequencies of driver gene variations, by race and ethnicity.
According to a single-center...
11/05/2024
Oncology
News
10/31/2024
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS assay was found to be feasible and accurate when detecting mutations in patients with advanced HR-positive, HER2-negative breast cancer.
A multi-gene target panel NGS...
10/31/2024
Oncology
FDA Approval
10/10/2024
Allison Casey
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib, with palbociclib and fulvestrant for patients with endocrine-resistant, PIK3CA-mutated HR-positive, HER2-negative locally advanced or metastatic breast cancer.
The FDA has approved inavolisib,...
10/10/2024
Oncology
News
10/02/2024
Allison Casey
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial provides the first prospective data that there is a protective effect with adjuvant advil among patients with resected, PIK3CA-mutant colon cancer.
The phase 3 SAKK 41/13 trial...
10/02/2024
Oncology
News
09/24/2024
Allison Casey
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is open for enrollment of patients with hormone receptor-positive, HER2-negative, PIK3CA-mutated locally advanced or metastatic breast cancer who progressed during or after a CDK4/6-inhibitor–based regimen.
The ongoing INAVO121 trial is...
09/24/2024
Oncology
Conference Coverage
12/08/2023
Stephanie Holland
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis results from the phase 3 INAVO120 trial, the addition of inavolisib to palbociclib plus fulvestrant significantly improved investigator-assessed progression-free survival in PIK3CA-mutated, hormone...
According to primary analysis...
12/08/2023
Oncology
FDA Approval
03/20/2026
Emily Estrada
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG 1826 trial, the FDA has approved nivolumab plus doxorubicin, vinblastine, and dacarbazine for previously untreated patients with advanced classical Hodgkin lymphoma.
Based on results from the SWOG...
03/20/2026
Oncology
News
03/18/2026
Emily Estrada
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative analysis of clinical trial data, botensilimab plus balstilimab provided a promising overall survival benefit in refractory MSS metastatic colorectal cancer.
According to a comparative...
03/18/2026
Oncology
News
03/11/2026
Stephanie Holland
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3 LITESPARK-011 trial demonstrate that belzutifan plus lenvatinib significantly improved progression-free survival compared with cabozantinib among previously treated patients with advanced clear cell renal cell...
Interim results from the phase 3...
03/11/2026
Oncology
News
03/11/2026
Stephanie Holland
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3 SUCCESSOR-2 trial demonstrate that mezigdomide plus carfilzomib and dexamethasone significantly improved PFS in patients with relapsed/refractory multiple myeloma versus carfilzomib and dexamethasone alone.
Interim results from the phase 3...
03/11/2026
Oncology
News
03/11/2026
Stephanie Holland
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY and CONDOR trials, the FDA has approved piflufolastat F 18 injection for the detection of PSMA-positive lesions in patients with prostate cancer.
Based on results from the OSPREY...
03/11/2026
Radiopharmaceutical Education Institute
FDA Alerts
03/11/2026
Stephanie Holland
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data from the ongoing SYMPHONY-1 trial, Ipsen has voluntarily withdrawn tazemetostat across all approved indications.
Based on emerging safety data...
03/11/2026
Oncology
News
03/11/2026
Stephanie Holland
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the phase 3 MANEUVER trial demonstrate that pimicotinib was associated with manageable and largely reversible adverse events among patients with symptomatic, unresectable tenosynovial giant cell tumor.
Updated safety results from the...
03/11/2026
Oncology
News
03/05/2026
Stephanie Holland
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST trial demonstrated that adjuvant cemiplimab significantly improved disease-free survival compared with placebo among patients with high-risk cSCC.
Results from the phase 3 C-POST...
03/05/2026
Oncology
FDA Approval
03/05/2026
Emily Estrada
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase 3 MajesTEC-3 trial, the FDA approved teclistamab plus daratumumab hyaluronidase for previously treated patients with relapsed or refractory multiple myeloma.
Based on results from the phase...
03/05/2026
Oncology
News
03/04/2026
Emily Estrada
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study demonstrated that Tokyo-172 BCG was noninferior to TICE BCG in patients with high-risk non-muscle invasive bladder cancer.
Results from the SWOG S162 study...
03/04/2026
Oncology

Quizzes

Quiz
09/25/2024
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the progression-free survival was for the inavolisib arm in the INAVO120 trial? Test your knowledge with our quick quiz.
Do you know what the...
09/25/2024
Oncology
Quiz
09/25/2024
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of patients with hormone receptor-positive, HER2-negative breast cancer have a PIK3CA mutation? Take our quick quiz to find out!
Do you know what percentage of...
09/25/2024
Oncology
Quiz
03/18/2026
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the clinical benefit of tucatinib plus trastuzumab therapy in patients with chemotherapy-refractory, HER2-positive, RAS wild-type metastatic colorectal cancer.
Test your knowledge of the...
03/18/2026
Oncology
Quiz
03/04/2026
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum LDH and α-HBDH levels following first-line chemoimmunotherapy may influence survival outcomes in extensive-stage small cell lung cancer (ES-SCLC).
Test your knowledge of how serum...
03/04/2026
Oncology
Quiz
03/03/2026
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a multi-omics model for predicting responses to whole-brain radiotherapy among patents with small cell lung cancer.
Test your knowledge on a...
03/03/2026
Oncology
Quiz
03/03/2026
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on safusidenib erbumine, a selective mutant IDH1 inhibitor, patients with newly diagnosed, chemotherapy- and radiotherapy-naïve grade 2 IDH1-mutated gliomas.
Test your knowledge on...
03/03/2026
Oncology
Quiz
03/02/2026
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the response rates and survival outcomes of chidamide, azacitidine, cytarabine, aclarubicin, G-CSF (CACAG), and venetoclax therapy for patients with R/R acute myeloid leukemia.
Test your knowledge on the...
03/02/2026
Oncology
Quiz
02/24/2026
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the safety profile of oral iberdomide plus low-dose cyclophosphamide and dexamethasone for patents with R/R multiple myeloma.
Test your knowledge on the...
02/24/2026
Oncology
Quiz
02/19/2026
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results from the phase 3 TROG 05.01 trial evaluating postoperative radiotherapy with or without concurrent chemotherapy in high-risk cutaneous squamous cell carcinoma of the head and neck.
Test your knowledge of results...
02/19/2026
Oncology
Quiz
02/05/2026
Test your knowledge of emerging biomarkers in small cell lung cancer, including whether proteomic analysis identified ISL1 as a predictive biomarker for lurbinectedin efficacy.
Test your knowledge of emerging biomarkers in small cell lung cancer, including whether proteomic analysis identified ISL1 as a predictive biomarker for lurbinectedin efficacy.
Test your knowledge of emerging...
02/05/2026
Oncology
Quiz
02/04/2026
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA approval of cemiplimab for adjuvant treatment of high-risk cutaneous squamous cell carcinoma based on results from the phase 3 C-POST trial.
Test your knowledge of the FDA...
02/04/2026
Oncology
Quiz
01/27/2026
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent study, berzosertib plus topotecan yielded meaningful clinical benefit for patients with relapsed, platinum-resistant small-cell lung cancer (SCLC) compared with historical outcomes from topotecan monotherapy.
True or false: In a recent...
01/27/2026
Oncology